drugset / Trial / NCT00240734

Treatment of Anemia in Diabetic Subjects With CKD

NCT00240734

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline by Week 17.

Timeline

Start
2005-03
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic Subcutaneous

Indications